Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

ID DOID:4971
Name myelofibrosis
Definition A myeloid neoplasm that is located in the bone marrow which results in bone marrow being replaced by fibrous (scar) tissue.
Source DiseaseOntology.org
Alt Ids DOID:5737
Path disease disease of cellular proliferation cancer organ system cancer hematologic cancer bone marrow cancer myeloid neoplasm myelofibrosis

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
JAK2 V617F N/A myelofibrosis not applicable detail...
IDH1 mutant N/A myelofibrosis not applicable detail...
IDH2 mutant N/A myelofibrosis not applicable detail...
DNMT3A mutant N/A myelofibrosis not applicable detail...
CBL mutant N/A myelofibrosis not applicable detail...
JAK2 V617F INCB053914 myelofibrosis predicted - sensitive detail...
JAK2 mutant N/A myelofibrosis not applicable detail...
TET2 mutant N/A myelofibrosis not applicable detail...
JAK2 V617F C220 myelofibrosis predicted - sensitive detail...
NRAS mutant N/A myelofibrosis not applicable detail...
JAK2 V617F Binimetinib + Ruxolitinib myelofibrosis sensitive detail...
JAK2 V617F Flonoltinib maleate myelofibrosis sensitive detail...
JAK2 V617F INCB160058 myelofibrosis predicted - sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT01398462 Phase I CWP232291 Phase I Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients Completed USA 1
NCT01644110 Phase Ib/II Pomalidomide + Ruxolitinib Ruxolitinib and Pomalidomide Combination Therapy in Patients With Primary and Secondary MF (POMINC) Active, not recruiting DEU 0
NCT01787487 Phase II Azacitidine + Ruxolitinib Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative Neoplasm Recruiting USA 0
NCT02098161 Phase II LCL161 LCL161 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis Completed USA 0
NCT02158858 Phase Ib/II CPI-0610 + Ruxolitinib CPI-0610 A Phase 2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis Active, not recruiting USA | POL | NLD | ITA | GBR | FRA | DEU | CAN | BEL 0
NCT02251821 Phase II Fludarabine Tacrolimus Mycophenolate mofetil Busulfan Pacritinib Momelotinib Melphalan Methotrexate Ruxolitinib Cyclophosphamide JAK-2 Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis Active, not recruiting USA 0
NCT02268253 Phase II Tagraxofusp-erzs Tagraxofusp (SL-401) in Patients With CMML or MF Completed USA | CAN 0
NCT02386800 FDA approved Ruxolitinib Panobinostat + Ruxolitinib CINC424A2X01B Rollover Protocol Active, not recruiting TUR | SWE | POL | LBN | ITA | ISR | HUN | GRC | FRA | ESP | DEU | CAN | BGR | BEL | AUS 10
NCT02421354 Phase II Nivolumab Study of Nivolumab in Patients With Myelofibrosis Terminated USA 0
NCT02440685 Phase Ib/II ASN002 A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors Terminated USA | ARG 0
NCT02493530 Phase I Ruxolitinib + Umbralisib TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea Completed USA 0
NCT02528877 Phase I Fludarabine + Melphalan Ruxolitinib + Sirolimus + Tacrolimus Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced Intensity Donor Hematopoietic Cell Transplant in Patients With Myelofibrosis Withdrawn USA 0
NCT02530034 Phase I Hu8F4 Hu8F4 in Treating Patients With Advanced Hematologic Malignancies Active, not recruiting USA 0
NCT02530619 Phase I Alisertib Alisertib in Treating Patients With Myelofibrosis or Relapsed or Refractory Acute Megakaryoblastic Leukemia Unknown status USA 0
NCT02564536 Phase I Decitabine + Pacritinib Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS) Withdrawn 0
NCT02718300 Phase II Parsaclisib + Ruxolitinib A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis Terminated USA 0
NCT02966353 Phase II Ruxolitinib Efficacy and Safety of Ruxolitinib in the Treatment of Anemic Myelofibrosis Patients. (REALISE) Completed TUR | ITA | GRC | ESP | DEU | CAN | BGR | BEL | AUT 2
NCT03042689 Phase I Regorafenib Study of Regorafenib in Patients With Advanced Myeloid Malignancies Completed USA 0
NCT03065400 Phase II Pembrolizumab PD-1 Inhibition in Advanced Myeloproliferative Neoplasms Completed USA 0
NCT03136185 Phase II IMG-7289 IMG-7289 in Patients With Myelofibrosis Completed USA | ITA | GBR | DEU | AUS 0
NCT03144687 Phase II Itacitinib + Ruxolitinib Itacitinib A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis Completed USA | NLD | AUT 0
NCT03165734 Phase II Lenalidomide Ruxolitinib Hydroxyurea Pacritinib Thalidomide A Phase 2/3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis (PACIFICA) Recruiting USA | ROU | POL | ITA | ISR | HUN | GBR | FRA | ESP | DEU | CZE | CAN | BGR | AUS 8
NCT03289910 Phase II Carboplatin + Topotecan + Veliparib Carboplatin + Topotecan Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia Active, not recruiting USA 0
NCT03326310 Phase I Azacitidine + Selumetinib Study of MEK Inhibitor Selumetinib in Combination With Azacitidine in Patients With Higher Risk Chronic Myeloid Neoplasia Recruiting USA 0
NCT03373877 Phase I PU-H71 + Ruxolitinib Evaluation of Ruxolitinib in Combination With PU-H71 for Treatment of Myelofibrosis Terminated USA 0
NCT03441113 Phase II Momelotinib Extended Access of Momelotinib in Adults With Myelofibrosis Active, not recruiting USA | ROU | POL | NLD | ITA | ISR | HUN | GBR | FRA | ESP | DNK | DEU | CAN | BGR | BEL | AUT | AUS 3
NCT03480360 Phase III Cyclophosphamide + Fludarabine Filgrastim + Mycophenolate mofetil + Tacrolimus Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression Active, not recruiting USA 0
NCT03592576 Expanded access Navitoclax Expanded Access to Navitoclax No longer available 0
NCT03627403 Phase II Selinexor Selinexor in Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors (ESSENTIAL) Active, not recruiting USA 0
NCT03645824 Phase II Pacritinib Myelofibrosis Treated With Pacritinib Before aSCT. (HOVON134MF) (HOVON134MF) Active, not recruiting NLD | BEL 0
NCT03662126 Phase II KRT-232 KRT-232 in Subjects With PMF, Post-PV MF, or Post-ET MF Who Have Failed a JAK Inhibitor Recruiting USA | TUR | ROU | POL | LTU | ITA | ISR | HUN | HRV | GRC | GBR | FRA | ESP | DEU | CZE | CAN | BRA | BGR | AUS | ARG 8
NCT03755518 Phase III Fedratinib An Efficacy and Safety Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib (FREEDOM) Completed USA | CAN 0
NCT03862157 Phase Ib/II Azacitidine + MLN4924 + Venetoclax Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Active, not recruiting USA 0
NCT03886831 Phase I PRT543 A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies Completed USA 0
NCT03895112 Phase I BMS-986416 MPN-RC 118 AVID200 in Myelofibrosis Completed USA 0
NCT03912064 Phase I Ipilimumab A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT Active, not recruiting USA 0
NCT03935555 Phase I PU-H71 Assess the Safety, Tolerability Oral PU-H71 in Subjects Taking Ruxolitinib Terminated USA 0
NCT03952039 Phase III Fedratinib An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib (FREEDOM2) Active, not recruiting POL | NLD | ITA | IRL | HUN | GBR | FRA | ESP | DEU | CZE | BEL | AUT | AUS 3
NCT04041050 Phase I Navitoclax Navitoclax + Ruxolitinib A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Alone and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm Active, not recruiting USA | TUR | SWE | ITA | HRV | GBR | FRA | ESP | DEU | BGR | BEL 3
NCT04089449 Phase I PRT811 A Study of PRT811 in Participants With Advanced Solid Tumors, Gliomas and Myelofibrosis Completed USA 0
NCT04173494 Phase III Danazol Momelotinib A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Patients (MOMENTUM) Completed USA | SWE | ROU | POL | NZL | ITA | ISR | HUN | GBR | FRA | ESP | DNK | DEU | CZE | CAN | BGR | BEL | AUT | AUS 3
NCT04176198 Phase I TP-3654 A Study of Oral TP-3654 in Patients With Myelofibrosis Recruiting USA | ITA | GBR | FRA | CAN | BEL | AUS 1
NCT04279847 Phase I INCB057643 Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms (LIMBER) Recruiting USA | NLD | ITA | GBR | FIN | ESP | CAN 1
NCT04281498 Phase II Enasidenib + Ruxolitinib Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation Completed USA | CAN 0
NCT04282187 Phase II Decitabine + Fedratinib Decitabine + Ruxolitinib Decitabine With Ruxolitinib or Fedratinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms Recruiting USA 0
NCT04454658 Phase I ABBV-744 ABBV-744 + Navitoclax ABBV-744 + Ruxolitinib Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis Active, not recruiting USA | TUR | SWE | ITA | ISR | HUN | ESP | BRA | BGR | AUS | ARG 3
NCT04468984 Phase III Navitoclax + Ruxolitinib Safety, Efficacy, and Assessment of Change in Spleen Volume Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet in Adult Participants With Relapsed/Refractory Myelofibrosis (TRANSFORM-2) Active, not recruiting USA | TUR | SWE | POL | NZL | ITA | ISR | HUN | HRV | GRC | GBR | FRA | ESP | DNK | DEU | CZE | CHE | CAN | BGR | BEL | AUT | AUS 7
NCT04472598 Phase III Ruxolitinib Navitoclax + Ruxolitinib Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis (TRANSFORM-1) Active, not recruiting USA | TUR | SWE | NZL | NLD | ITA | ISR | HRV | GRC | GBR | FRA | ESP | DEU | CAN | BGR | BEL | AUT | AUS 7
NCT04480086 Phase I Mivebresib + Navitoclax Mivebresib + Ruxolitinib Mivebresib Safety and Tolerability Study of Mivebresib Tablet Alone or in Combination With Ruxolitinib Tablet or Navitoclax Tablet in Adult Participants With Myelofibrosis Terminated USA 2
NCT04485260 Phase Ib/II KRT-232 + Ruxolitinib An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to Ruxolitinib Unknown status USA | POL | ITA | ISR | FRA | ESP | DEU | BGR | AUS 0
NCT04517851 Phase I Elotuzumab Elotuzumab for the Treatment of JAK2-Mutated Myelofibrosis Active, not recruiting USA 0
NCT04551053 Phase III Parsaclisib + Ruxolitinib Ruxolitinib To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304) Terminated USA | TUR | ROU | POL | NOR | ITA | ISR | HUN | GBR | FRA | FIN | ESP | DEU | BEL | AUT 4
NCT04551066 Phase III Ruxolitinib Parsaclisib + Ruxolitinib To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313) Active, not recruiting USA | TUR | POL | NOR | ITA | ISR | GBR | FRA | FIN | ESP | DNK | DEU | BEL | AUT 3
NCT04562389 Phase III Ruxolitinib + Selinexor Ruxolitinib Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis Recruiting USA | ROU | POL | NLD | ITA | ISR | HUN | GRC | GBR | FRA | ESP | DNK | DEU | CZE | CAN | BGR | BEL 3
NCT04576156 Phase III Thalidomide Danazol Hydroxyurea Imetelstat A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment Recruiting USA | TUR | POL | ITA | ISR | HUN | GBR | FRA | ESP | DNK | DEU | BRA | BGR | BEL | AUT | AUS | ARG 9
NCT04603495 Phase III CPI-0610 + Ruxolitinib Ruxolitinib Study of CPI-0610 in Myelofibrosis (MF) (MANIFEST-2) Active, not recruiting USA | TUR | POL | NLD | ITA | ISR | HUN | GRC | GBR | FRA | ESP | DEU | CZE | CAN | BEL | AUT | AUS 5
NCT04629508 Phase II Itacitinib To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy. Completed USA | POL | ITA | ESP | DEU | BEL | AUT 0
NCT04655118 Phase II TL-895 Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis Recruiting USA | POL | ITA | HUN | FRA | ESP | DEU | BRA | BGR | BEL | AUS 2
NCT04676529 Phase Ib/II PXS-5505 Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of PXS-5505 in Patients With Primary, Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis Active, not recruiting USA | AUS 2
NCT04771572 Phase I LP-118 Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL. Recruiting USA 0
NCT04817007 Phase I BMS986158 + Ruxolitinib BMS986158 + CYC065 BMS986158 A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis) Active, not recruiting USA | ROU | POL | ITA | ISR | HUN | GRC | FRA | ESP | DEU | AUS 1
NCT04854096 Phase II Ilginatinib Study to Assess Efficacy and Safety of NS-018 Compared to BAT in Patients With Myelofibrosis Terminated USA | TUR | POL | ITA | GBR | DEU 3
NCT04878003 Phase II TL-895 KRT-232 Study of KRT-232 or TL-895 in Janus Associated Kinase Inhibitor Treatment-Naive Myelofibrosis Recruiting USA | POL | BGR 6
NCT04896112 Phase I LNK01002 A Study of LNK01002 in Patients With Primary (PMF) or Secondary Myelofibrosis (PV-MF, ET-MF) or Acute Myeloid Leukemia Withdrawn USA 0
NCT04955938 Phase I Enasidenib + Fedratinib Fedratinib + Ivosidenib A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms Withdrawn USA 0
NCT05127174 Phase Ib/II Fedratinib Maintenance Fedratinib to Prevent Post-Transplant Relapse in Myeloproliferative Neoplasms Active, not recruiting USA 0
NCT05455294 Phase I Decitabine + Navitoclax + Venetoclax Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms Active, not recruiting USA 0
NCT05467800 Phase II Canakinumab Study of Canakinumab in Patients With Myelofibrosis Active, not recruiting USA 0
NCT05714072 Phase I Abemaciclib + Ruxolitinib A Study of Ruxolitinib in Combination With Abemaciclib for the Treatment of Myelofibrosis Recruiting USA 0
NCT05835466 Phase II Reparixin Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120) Recruiting USA 0
NCT05936359 Phase I INCA033989 INCA033989 + Ruxolitinib A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms Recruiting ITA | GBR | FRA | ESP | DNK | DEU | CAN | AUS 1
NCT06034002 Phase I INCA033989 A Study to Evaluate INCA033989 Administered in Participants With Myeloproliferative Neoplasms Recruiting USA 0
NCT06150157 Phase I JNJ-88549968 A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms Recruiting USA | GBR | FRA | ESP | DEU | CAN 0
NCT06218628 Phase I Pacritinib + Talazoparib Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition Recruiting USA 0
NCT06291987 Phase I Ivosidenib + Ruxolitinib Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation (MPN) Recruiting USA 0
NCT06313593 Phase I INCB160058 A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms Recruiting USA 0
NCT06327100 Phase II Tasquinimod Ruxolitinib + Tasquinimod Open Label Phase 2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF) Recruiting USA 0
NCT06343805 Phase I AJ1-11095 A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i) Recruiting USA 0